Assignee
BIO PATH HOLDINGS INC
US·10 granted patents·3 pending applications·34 citations·filing 2016–2024
Top patents by PatentIndex Score
13 records- 0192US9744187B2p-Ethoxy nucleic acids for liposomal formulationBIO-PATH HOLDINGS INC·Filed 2016·Granted Aug 29, 2017·14 cites·29 claims
- 0288US10335428B2P-ethoxy nucleic acids for liposomal formulationBIO PATH HOLDINGS INC·Filed 2017·Granted Jul 2, 2019·7 cites·20 claims
- 0387US10898506B2P-ethoxy nucleic acids for liposomal formulationBIO PATH HOLDINGS INC·Filed 2019·Granted Jan 26, 2021·5 cites·29 claims
- 0485US11041153B2P-ethoxy nucleic acids for STAT3 inhibitionBIO PATH HOLDINGS INC·Filed 2018·Granted Jun 22, 2021·4 cites·34 claims
- 0585US10927379B2Combination therapy with liposomal antisense oligonucleotidesBIO PATH HOLDINGS INC·Filed 2017·Granted Feb 23, 2021·4 cites·56 claims
- 0679US2025255897A1P-ethoxy nucleic acids for liposomal formulationBIO PATH HOLDINGS INC·Filed 2024·Application pending·0 cites
- 0773US12097214B2P-ethoxy nucleic acids for liposomal formulationBIO PATH HOLDINGS INC·Filed 2020·Granted Sep 24, 2024·0 cites·28 claims
- 0868US12472199B2P-ethoxy nucleic acids for IGF-1R inhibitionBIO PATH HOLDINGS INC·Filed 2021·Granted Nov 18, 2025·0 cites·4 claims
- 0966US12319911B2P-ethoxy nucleic acids for STAT3 inhibitionBIO PATH HOLDINGS INC·Filed 2021·Granted Jun 3, 2025·0 cites·21 claims
- 1066US12012601B2Combination therapy with liposomal antisense oligonucleotidesBIO PATH HOLDINGS INC·Filed 2021·Granted Jun 18, 2024·0 cites·19 claims
- 1157US2020038429A1P-ethoxy nucleic acids for igf-1r inhibitionBIO PATH HOLDINGS INC·Filed 2018·Application pending·0 cites
- 1245US12234457B2P-ethoxy nucleic acids for BCL2 inhibitionBIO PATH HOLDINGS INC·Filed 2018·Granted Feb 25, 2025·0 cites·26 claims
- 1343US2021115451A1P-ethoxy nucleic acids for igf-1r inhibitionBIO PATH HOLDINGS INC·Filed 2018·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →